Philips Launches Rapid Equipment Deployment Kit to COVID-19 Response

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, introduced its Rapid Equipment Deployment Kit for ICU ramp-ups, allowing doctors, nurses, technicians and hospital staff to quickly support critical care patient monitoring capabilities during the COVID-19 pandemic. Currently successfully in use in the first health systems across the US [1], the Rapid Equipment Deployment Kit combines Philips advanced patient monitoring technology with predictive patient centric algorithms enabling care teams to quickly scale up critical care patient monitoring capabilities within a few hours [2]. As health systems in the U.S. continue to experience surges in critical care and emergency care demand related to the COVID-19 crisis, the kit provides hospitals a way to quickly and easily expand their critical care capacity.

Innovative approach to help manage capacity surge in the ICU

The Philips Rapid Equipment Deployment Kit is a fully configured and ready-to-deploy ICU patient monitoring solution, which includes 20 ICU monitors, 20 measurement servers and one central management monitoring station. The kits are pre-built, pre-configured and pre-packed into sturdy cases that can elevate a hospital’s general care area to a critical care level in a matter of hours [3]. Kits are complete with step-by-step instructions allowing the pre-configured system to be deployed by hospital staff, with remote technical and clinical support from Philips. Kits can be transferred from hospital to hospital as needed. Once a crisis/surge passes, the kits are disinfected, packed up and stored to have available in preparation for future emergencies.

"The current health crisis has demonstrated a clear need for us to deliver innovative solutions to our customers that provide a complete critical care monitoring solution with all of the equipment they require on demand. This eliminates the need to source and configure individual pieces of high-demand equipment during a crisis," said Peter Ziese, General Manager of Monitoring Analytics at Philips. "To help ensure economical and more efficient use of hospital resources, the Rapid Equipment Deployment Kits provide the speed, flexibility and ease of implementation for advanced critical care patient monitoring that many of our customers must have during this most pressing time."

Philips critical care patient monitoring solutions

In June, Philips announced it had received Emergency Use Authorization from the FDA for Philips' IntelliVue Patient Monitors MX750/MX850 and its IntelliVue Active Displays AD75/AD85, for use in the US during the COVID-19 health emergency [4]. These patient monitoring solutions support infection-control protocols and remotely provide critical patient information when caring for hospitalized COVID-19 patients. The MX750 and MX850 monitors are the latest additions to Philips’ portfolio of integrated patient monitoring solutions to help support improved clinical and operational workflows. Updated features, include enhancements to monitor and assess clinical and network device performance, and additional functionalities to strengthen cybersecurity. Visit Philips critical care patient monitoring for more information on the Rapid Equipment Deployment Kits in the US market and Philips full suite of critical care patient monitoring solutions.

Philips COVID-19 solutions portfolio

Philips has a comprehensive portfolio of services and solutions to help support the delivery of high-quality care to COVID-19 patients. Solutions include secure, connected and intelligent approaches to diagnosis, treatment and predictive monitoring in the hospital, plus screening, remote patient monitoring and care at home. With healthcare under more pressure than ever before, Philips’ telehealth and AI-enabled data analytics can help support workflows, facilitate remote collaboration and optimize resources. Philips' COVID-19-related solutions are designed for rapid deployment and scalability. For more information on how Philips is addressing COVID-19 globally, please visit the Philips centralized COVID-19 hub.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries.

1. Philips Rapid Equipment Deployment Kits are available in the US market only. Kits are available in the US market only.
2. Compared to Philips' standard delivery time of 12-16 weeks. Average time for delivery is 7 days as of July 2020.
3. Compared to Philips' standard go-live of 5-7 days upon arrival. Average time for go-live is 5 hours as of July 2020.
4. The status of the Emergency Use Authorization can be found on the FDA website.

Most Popular Now

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

A Novel AI-Based Method Reveals How Cell…

Researchers from Tel Aviv University have developed an innovative method that can help to understand better how cells behave in changing biological environments, such as those found within a cancerous...